伊伐布雷定联合沙库巴曲缬沙坦治疗慢性心力衰竭的疗效及心率变异性分析  

Exploring the Efficacy and Heart Rate Variability of Ivabradine Combined with Sacubitril Valsartan in Chronic Heart Failure Treatment

作　　者：倪扬 罗慧敏 Ni Yang;Luo Huimin(Pharmacy Department of Zhongnan Hospital,Wuhan University,Wuhan 430071,China;Department of Cardiology,Zhongnan Hospital,Wuhan University,Wuhan 430071,China)

机构地区：[1]武汉大学中南医院药学部,湖北武汉430071 [2]武汉大学中南医院心内科,湖北武汉430071

出　　处：《转化医学杂志》2024年第9期1536-1541,共6页Translational Medicine Journal

基　　金：湖北省卫生和计划生育委员会中医药中西医结合科研项目(2013Z-Y47)。

摘　　要：目的 探讨伊伐布雷定联合沙库巴曲缬沙坦治疗慢性心力衰竭的疗效及心率变异性。方法 回顾性分析武汉大学中南医院2022年10月至2023年10月接诊慢性心力衰竭患者临床资料,依据治疗方式不同将其分为对照组和观察组,每组90例。对照组患者应用沙库巴曲缬沙坦治疗,观察组应用伊伐布雷定联合沙库巴曲缬沙坦治疗。对比2组患者的治疗效果、心功能指标、心率变异性指标及血清可溶性机制裂解素2(sST-2)、可溶性细胞间黏附因子1(sICAM-1)、N末端利钠肽前体(NT-proBNP)。结果 观察组患者治疗有效率明显高于对照组(P <0.05);观察组患者治疗后左室射血分数(LVEF)、左室舒张末期内径(LVEDd)、心率变异性指标以及血清sST-2、sICAM-1、NTproBNP水平均低于对照组(P均<0.05)。结论 伊伐布雷定联合沙库巴曲缬沙坦可有效改善慢性心力衰竭患者的心功能指标、心率变异性,降低血清sST-2、sICAM-1、NT-proBNP水平,治疗效果显著,值得临床推广。Objective To explore the efficacy and heart rate variability of ivabradine combined with sacubitril valsartan in the treatment of chronic heart failure.Methods A total of 180 patients with heart failure treated at Zhongnan Hospital,Wuhan University,from October 2022 to October 2023 were retrospectively analyzed.Patients were divided into a reference group(n=90,treated with sacubitril valsartan)and a study group(n=90,treated with ivabradine combined with sacubitril valsartan).The therapeutic effects,cardiac function indices,heart rate variability indices,and serum levels of soluble suppression of tumorigenicity 2(sST-2),soluble intercellular adhesion molecule-1(sICAM-1),and N-terminal pro-brain natriuretic peptide(NT-proBNP)were compared between the two groups.Results The effective treatment rate in the study group was significantly higher than that in the reference group(P<0.05).The study group showed significantly improved left ventricular ejection fraction(LVEF)and reduced LVEDd compared to the reference group(P<0.05).Heart rate variability indices and serum levels of sST-2,sICAM-1,and NT-proBNP were significantly reduced in the study group compared to the reference group after treatment(P<0.05).Conclusion The combination of ivabradine and sacubitril valsartan effectively improves cardiac function indices,enhances treatment efficiency,and lowers serum sST-2,sICAM-1,and NT-proBNP levels in heart failure patients.The treatment shows significant therapeutic effects and is worthy of clinical application.

关 键 词：伊伐布雷定 沙库巴曲缬沙坦 心衰 可溶性机制裂解素2 心率变异性 

分 类 号：R541.61[医药卫生—心血管疾病]